Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.

[1]  R. Berkowitz,et al.  Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC) , 2019, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[2]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[3]  P. Dey,et al.  The chemotherapy response score is a useful histological predictor of prognosis in high‐grade serous carcinoma , 2018, Histopathology.

[4]  S. Avril,et al.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors , 2017, Der Pathologe.

[5]  B. Monk,et al.  FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. , 2017, Gynecologic oncology.

[6]  Young Tae Kim,et al.  External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma , 2017, Journal of gynecologic oncology.

[7]  R. L. Hollis,et al.  Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer , 2017, OncoTargets and therapy.

[8]  M. Bulsara,et al.  Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma , 2017, International Journal of Gynecologic Cancer.

[9]  Ali Bashashati,et al.  Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes , 2017, Nature Genetics.

[10]  A. Shimomura,et al.  The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma , 2017, International Journal of Gynecologic Cancer.

[11]  C. Gilks,et al.  The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[12]  M. Köbel,et al.  Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR) , 2015, Modern Pathology.

[13]  H. Kitchener,et al.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.

[14]  A. Tinker,et al.  Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Scambia,et al.  Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. , 2014, American journal of obstetrics and gynecology.

[16]  Observational Studies: Getting Clear about Transparency , 2014, PLoS medicine.

[17]  K. Hess,et al.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.

[18]  M. Parmar,et al.  Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) , 2010, International Journal of Gynecologic Cancer.

[19]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[20]  Carol L. Brown,et al.  Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Höfler,et al.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.

[22]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.

[24]  Young Tae Kim,et al.  Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer. , 2018, Gynecologic oncology.

[25]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[26]  K. Hess,et al.  Association of BRCA 1 and BRCA 2 Mutations With Survival , Chemotherapy Sensitivity , and Gene Mutator Phenotype in Patients With Ovarian Cancer , 2011 .

[27]  O. Dworak,et al.  Pathological features of rectal cancer after preoperative radiochemotherapy , 1997, International Journal of Colorectal Disease.